AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23550096 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary sodium nitrite
Number of subjects: 80
Study 23550096 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sodium chloride)
Number of subjects: 80
Study 23551108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein drink (325 mL) with ice chips/water PRN
Number of subjects: 150
Study 23551108 — intervention group
Group type: COMPARATOR
Intervention: Ice chips/water PRN (Control)
Number of subjects: 150
Study 23551108 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein drink (325 mL)
Number of subjects: 150
Study 23551108 — intervention group
Group type: COMPARATOR
Intervention: Ice chips/water (Control)
Number of subjects: 150
Study 23551593 — intervention group
Group type: EXPERIMENTAL
Intervention: everolimus 10 mg orally once daily continuously (one cycle = 4 weeks)
Number of subjects: 45
Study 23551918 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa administration for joint bleeds in children
Number of subjects: 52
Study 23551918 — intervention group
Group type: EXPERIMENTAL
Intervention: rFVIIa administration for joint bleeds in adults
Number of subjects: 52
Study 23551933 — intervention group
Group type: EXPERIMENTAL
Intervention: 2009 trivalent inactivated split-virion influenza vaccine (TIV) 0.25 ml (22.5 μg haemagglutinin) or 0.5 ml (45 μg) depending on age and prior vaccination history
Number of subjects: 1992
Study 23552982 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with grades III and IV toxic effects
Number of subjects: 2670
Study 23552982 — intervention group
Group type: EXPERIMENTAL
Intervention: Metastatic disease at diagnosis
Number of subjects: 2670
Study 23552982 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor tolerance of neoadjuvant treatment
Number of subjects: 2670
Study 23552982 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers performing at least 10 resections per year
Number of subjects: 2670
Study 23553066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin (100 mg/m2), docetaxel (35 mg/m2), and vandetanib (100 mg PO daily)
Number of subjects: 9
Study 23553066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxaliplatin (80 mg/m2), docetaxel (30 mg/m2), and vandetanib (100 mg PO daily)
Number of subjects: 9
Study 23553119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel, 0.015%, daily for 3 consecutive days for face or scalp lesions.
Number of subjects: 184
Study 23553119 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingenol mebutate gel, 0.05%, daily for 2 consecutive days for trunk or extremity lesions.
Number of subjects: 184
Study 23553159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fava beans (dietary intervention)
Number of subjects: 13
Study 23553159 — intervention group
Group type: COMPARATOR
Intervention: Control diet (fixed-sodium diet)
Number of subjects: 13
Study 23553162 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw fruit consumption
Number of subjects: 4680
Study 23553162 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrus fruit intake
Number of subjects: 4680
Study 23553162 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple intake
Number of subjects: 4680
Study 23553162 — intervention group
Group type: EXPERIMENTAL
Intervention: Banana intake
Number of subjects: 4680
Study 23553162 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit juice intake
Number of subjects: 4680
Study 23553164 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary disinhibition (HD)
Number of subjects: 30
Study 23553164 — intervention group
Group type: COMPARATOR
Intervention: Low dietary disinhibition (LD)
Number of subjects: 30
Study 23553164 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (HD and LD)
Number of subjects: 30
Study 23553682 — intervention group
Group type: EXPERIMENTAL
Intervention: Total body computed tomography (TB-CT) scan
Number of subjects: 240
Study 23553848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 40 mg daily
Number of subjects: 34
Study 23553848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib 20 mg daily
Number of subjects: 34
Study 23553848 — intervention group
Group type: COMPARATOR
Intervention: Cabozantinib 100 mg daily
Number of subjects: 34
Study 23554030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (300 mg/m²/day) and Temozolomide (150 mg/m²/day)
Number of subjects: 19
Study 23554856 — intervention group
Group type: EXPERIMENTAL
Intervention: qPCR
Number of subjects: 30
Study 23554856 — intervention group
Group type: EXPERIMENTAL
Intervention: PfHRP-2 ELISA
Number of subjects: 30
Study 23554856 — intervention group
Group type: EXPERIMENTAL
Intervention: pLDH ELISA
Number of subjects: 30
Study 23554856 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 30
Study 23555538 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (75 mg/day)
Number of subjects: 431
Study 23555538 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/day)
Number of subjects: 431
Study 23555589 — intervention group
Group type: EXPERIMENTAL
Intervention: Natalizumab treatment
Number of subjects: 195
Study 23557023 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort SMART(®), 160/4.5 μg) twice daily plus as needed
Number of subjects: 862
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation (MV)
Number of subjects: 773
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 773
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute respiratory distress syndrome (ARDS)
Number of subjects: 773
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative fluid balance over the first 72 hours of ICU
Number of subjects: 773
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher lactate levels
Number of subjects: 773
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of associated organ dysfunctions
Number of subjects: 773
Study 23557378 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive fluid balance
Number of subjects: 773
Study 23557395 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent covering of the side branch (group A)
Number of subjects: 98
Study 23557395 — intervention group
Group type: COMPARATOR
Intervention: Control group (group B)
Number of subjects: 98
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy eyes
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucoma suspects
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Early glaucoma
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate glaucoma
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced glaucoma
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Glaucomatous eyes
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between CDR measurements
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: RGC estimates and CDR relationship
Number of subjects: 336
Study 23557744 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in CDR
Number of subjects: 336
Study 23557757 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1,500 mg/day) for 16 weeks
Number of subjects: 7
Study 23557757 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-insulin-resistant women), n = 5
Number of subjects: 7
Study 23557820 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 31
Study 23557866 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin or Amikacin
Number of subjects: 0
Study 23557865 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous patient-controlled analgesia with fentanyl
Number of subjects: 196
Study 23557865 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic polymorphisms (OPRM1 118A>G, ABCB1 2677G>A/T, ABCB1 3435C>T, CYP3A4*18, CYP3A5*3)
Number of subjects: 196
Study 23558394 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-40 mg/day) during level 1 treatment
Number of subjects: 1928
Study 23558394 — intervention group
Group type: EXPERIMENTAL
Intervention: Switch to sertraline, sustained-release bupropion, or extended-release venlafaxine or augmentation with sustained-release bupropion or buspirone during level 2 treatment
Number of subjects: 1928
Study 23558394 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial treatment responders
Number of subjects: 1928
Study 23558394 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-step treatment responders
Number of subjects: 1928
Study 23558394 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with treatment resistance
Number of subjects: 1928
Study 23558599 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 90
Study 23558599 — intervention group
Group type: EXPERIMENTAL
Intervention: Elbow flexor muscle strength
Number of subjects: 90
Study 23558599 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadriceps peak torque
Number of subjects: 90
Study 23558599 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamstrings peak torque
Number of subjects: 90
Study 23558599 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal inspiratory pressure
Number of subjects: 90
Study 23558599 — intervention group
Group type: EXPERIMENTAL
Intervention: Fatigue Assessment Scale
Number of subjects: 90
Study 23558660 — intervention group
Group type: EXPERIMENTAL
Intervention: Zilver Vena stent
Number of subjects: 20
Study 23558847 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation science principles and frameworks applied in intervention research
Number of subjects: 0
Study 23558847 — intervention group
Group type: EXPERIMENTAL
Intervention: Established programs in hospice and palliative care
Number of subjects: 0
Study 23558847 — intervention group
Group type: EXPERIMENTAL
Intervention: Well-tested programs introduced in new settings
Number of subjects: 0
Study 23558847 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions maximizing cost-effectiveness
Number of subjects: 0
Study 23559086 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral macimorelin
Number of subjects: 98
Study 23559086 — intervention group
Group type: COMPARATOR
Intervention: Arginine+GHRH
Number of subjects: 98
Study 23559355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-profile breast implants
Number of subjects: 4412
Study 23559355 — intervention group
Group type: COMPARATOR
Intervention: Low- to moderate-profile breast implants
Number of subjects: 4412
Study 23560296 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected body surface area (BSA) > 25%
Number of subjects: 1541
Study 23560296 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected body surface area (BSA) > 25% and vitiligo lesions in the genital area
Number of subjects: 1541
Study 23560297 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic children (n=155) with excess adiposity (body mass index ≥85th percentile)
Number of subjects: 409
Study 23560297 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic children (n=155) with obesity (body mass index ≥95th percentile)
Number of subjects: 409
Study 23560297 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe psoriasis children (n=43)
Number of subjects: 409
Study 23560297 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild psoriasis children (n=27)
Number of subjects: 409
Study 23560297 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=42)
Number of subjects: 409
Study 23560297 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriatic children (n=409)
Number of subjects: 409
Study 23560574 — intervention group
Group type: EXPERIMENTAL
Intervention: NeuroBlate System (laser interstitial thermal therapy)
Number of subjects: 10
Study 23561231 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (SSRI), treated for 12 weeks
Number of subjects: 2280
Study 23562618 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation to the supero-lateral branch of the medial forebrain bundle
Number of subjects: 7
Study 23562852 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20-60mg/day) for 8 weeks
Number of subjects: 201
Study 23563126 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal Impulse and Rotor Modulation (FIRM) followed by conventional ablation
Number of subjects: 101
Study 23563126 — intervention group
Group type: COMPARATOR
Intervention: Conventional ablation alone
Number of subjects: 101
Study 23563126 — intervention group
Group type: EXPERIMENTAL
Intervention: All sources ablated
Number of subjects: 101
Study 23563126 — intervention group
Group type: EXPERIMENTAL
Intervention: Some sources ablated
Number of subjects: 101
Study 23563126 — intervention group
Group type: EXPERIMENTAL
Intervention: No sources ablated
Number of subjects: 101
Study 23563210 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab with chemotherapy (docetaxel, cyclophosphamide, followed by doxorubicin) every 3 weeks for 4 cycles, then surgery, followed by bevacizumab every 3 weeks for 9 cycles.
Number of subjects: 40
Study 23564195 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy for CAP patients (mean duration = 11.1 days)
Number of subjects: 362
Study 23564195 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic therapy for AECOPD patients (mean duration = 8.9 days)
Number of subjects: 362
Study 23564195 — intervention group
Group type: COMPARATOR
Intervention: Blood culture
Number of subjects: 362
Study 23564195 — intervention group
Group type: COMPARATOR
Intervention: Urinary antigen tests for Legionella pneumophila
Number of subjects: 362
Study 23564195 — intervention group
Group type: COMPARATOR
Intervention: Sputum investigation
Number of subjects: 362
Study 23564936 — intervention group
Group type: EXPERIMENTAL
Intervention: GP-organised follow-up
Number of subjects: 110
Study 23564997 — intervention group
Group type: EXPERIMENTAL
Intervention: Central fat mass (CFM) assessment via DEXA in subjects with OSAS (AHI ≥ 15)
Number of subjects: 749
Study 23564997 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for mild OSAS cases (15 < AHI < 30)
Number of subjects: 749
Study 23564997 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for severe OSAS cases (AHI > 30)
Number of subjects: 749
Study 23565175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee extensor strength
Number of subjects: 69
Study 23565175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic (60°/s) knee extensor strength
Number of subjects: 69
Study 23565175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic (60°/s) knee flexor strength
Number of subjects: 69
Study 23565175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric knee extensor strength (adjusted for age, sex, pain severity, BMI, peak VO2)
Number of subjects: 69
Study 23565175 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic knee extensor strength (adjusted for age, sex, pain severity, BMI, peak VO2)
Number of subjects: 69
Study 23565181 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg BID for 8 weeks
Number of subjects: 20
Study 23565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for hypertension
Number of subjects: 15773
Study 23565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for hyperglycaemia
Number of subjects: 15773
Study 23565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacological treatment for dyslipidaemia
Number of subjects: 15773
Study 23565931 — intervention group
Group type: EXPERIMENTAL
Intervention: CVD risk profile
Number of subjects: 15773
Study 23565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment targets for haemoglobin A1c, LDL, HDL, non-HDL cholesterol, systolic BP, BMI, waist circumference
Number of subjects: 15773
Study 23565931 — intervention group
Group type: EXPERIMENTAL
Intervention: Unmet therapeutic targets
Number of subjects: 15773
Study 23566357 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline (1.4 mg/kg for six months)
Number of subjects: 11
Study 23566574 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23567354 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS (Postprandial Distress Syndrome)
Number of subjects: 138
Study 23567354 — intervention group
Group type: EXPERIMENTAL
Intervention: EPS (Epigastric Pain Syndrome)
Number of subjects: 138
Study 23567354 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS and EPS overlap
Number of subjects: 138
Study 23567354 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Dyspepsia
Number of subjects: 138
Study 23568645 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard clinical management for heart failure (HF) including 12-lead ECG and transthoracic echocardiography at baseline, followed over 3 years.
Number of subjects: 5000
Study 23569312 — intervention group
Group type: EXPERIMENTAL
Intervention: PD0332991 200 mg orally once per day for 14 consecutive days in 21-day cycles
Number of subjects: 30
Study 23569312 — intervention group
Group type: EXPERIMENTAL
Intervention: PD0332991
Number of subjects: 30
Study 23569315 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading, then 2 mg/kg once per week) and lapatinib (1000 mg once per day for 12 weeks)
Number of subjects: 66
Study 23569315 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab and lapatinib with letrozole (plus LHRH agonist if premenopausal) for ER-positive tumors
Number of subjects: 66
Study 23572214 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal endoscopic total mesorectal excision (TME) with laparoscopic assistance
Number of subjects: 5
Study 23572474 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 23573223 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal Cognitive Assessment (MoCA)
Number of subjects: 0
Study 23573223 — intervention group
Group type: COMPARATOR
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 0
Study 23574119 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-EPOCH-R therapy
Number of subjects: 51
Study 23574119 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective analysis of DA-EPOCH-R
Number of subjects: 51
Study 23574764 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized Clinical Decision Support System (CDSS) for antenatal care and care during delivery and up to 24 hours post delivery.
Number of subjects: 0
Study 23574764 — intervention group
Group type: EXPERIMENTAL
Intervention: CDSS implementation in rural primary health care centers.
Number of subjects: 0
Study 23575255 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 3207
Study 23575255 — intervention group
Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 3207
Study 23575256 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting insulin levels
Number of subjects: 4425
Study 23575334 — intervention group
Group type: EXPERIMENTAL
Intervention: VNTR typing of M. intracellulare
Number of subjects: 70
Study 23575363 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+/KDR+/CD45- cells
Number of subjects: 155
Study 23575363 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133+/KDR+/CD45- cells
Number of subjects: 155
Study 23575363 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in CD34+/KDR+/CD45- cells
Number of subjects: 155
Study 23575363 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in CD133+/KDR+/CD45- cells
Number of subjects: 155
Study 23575918 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (AIs)
Number of subjects: 268
Study 23575918 — intervention group
Group type: COMPARATOR
Intervention: Postmenopausal comparison group (no AIs)
Number of subjects: 268
Study 23576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of riboflavin, folate, choline, and betaine
Number of subjects: 30
Study 23576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood biomarkers of riboflavin, vitamin B-6, active vitamin B-12 (holotranscobalamin), and betaine
Number of subjects: 30
Study 23576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis between dietary intakes and blood biomarkers
Number of subjects: 30
Study 23576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal switch between the betaine and folate pathways
Number of subjects: 30
Study 23576045 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural variations in food-consumption patterns
Number of subjects: 30
Study 23576267 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment twice weekly for 4 weeks
Number of subjects: 33
Study 23576625 — intervention group
Group type: EXPERIMENTAL
Intervention: CERE-120 (AAV2-neurturin) administered bilaterally to the substantia nigra and putamen
Number of subjects: 6
Study 23577182 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone 200 mg twice daily for 4 weeks
Number of subjects: 6
Study 23578144 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine therapy using a mixture of four novel peptides (VEGFR1, VEGFR2, URLC10, TTK/CDCA1) administered weekly by subcutaneous injection with montanide ISA-51 adjuvant.
Number of subjects: 15
Study 23578775 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine attacks
Number of subjects: 78
Study 23578816 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial EHR with robust clinical decision support (CDS)
Number of subjects: 16
Study 23578816 — intervention group
Group type: EXPERIMENTAL
Intervention: System refinements in EHR
Number of subjects: 16
Study 23578816 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial EHR with advanced CDS
Number of subjects: 16
Study 23578923 — intervention group
Group type: EXPERIMENTAL
Intervention: Irisin levels
Number of subjects: 17
Study 23578923 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions designed to increase irisin action
Number of subjects: 17
Study 23579255 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel (HS)
Number of subjects: 95
Study 23579255 — intervention group
Group type: COMPARATOR
Intervention: Electric scalpel (ES)
Number of subjects: 95
Study 23580693 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for primary breast cancer
Number of subjects: 2411
Study 23580693 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection
Number of subjects: 2411